BVS857 Clinical Trial Yields Mixed Results

Novartis Pharmaceuticals‘ investigational compound BVS857 significantly improved muscle volume in patients with X-linked type spinal muscular atrophy (SMA) over a short period of time, Phase 2 clinical results show. However, the compound failed to improve muscle strength and function.

These findings were reported in the study, “Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial,” published in The Lancet Neurology.

X-linked type SMA, also known as spinal and bulbar muscular atrophy (SBMD), or Kennedy’s disease, is caused by a faulty androgen receptor (AR) gene and is characterized by degeneration of muscle and lower motor neurons of the brain stem and spinal cord.

Previous studies have shown that patients with this disease have low amounts (less than 170 ng/mL) of insulin-like growth factor-1 (IGF-1) in the blood. Also, cellular and mouse studies have suggested that by increasing the amount of this signaling molecule it may be possible to ease the features of AR gene mutations.

IGF-1 is a growth factor with different roles in many aspects of childhood growth. It also plays an important role in adult metabolism.

Novartis developed the artificial compound BVS857 specifically to mimic the natural activity of the IGF-1 hormone, while holding enhanced efficiency. This molecule is capable of IGF-1 receptor activation, but has a longer half-life — the time it takes for the body to eliminate half of the substance — than IGF-1.

The safety and effectiveness of BVS857 was evaluated in a Phase 2 trial (NCT02024932) in adult patients with genetically confirmed Kennedy’s disease recruited at six clinical sites in Denmark, Germany, Italy, and the United States. Patients were at least 18 years old, were ambulatory, had muscle weakness and IGF-1 blood serum levels below 170 ng/mL.

The study was divided into two parts. The first part included eight patients who received increasing doses of the investigational compound or a placebo. In the second part, 27 patients received weekly intravenous injections of 0.06 mg/kg BVS857 or placebo for up to 12 weeks.

During the study 89% and 94% of the patients in the placebo and BVS857 groups, respectively, experienced at least one adverse side effect, with the proportion of moderate adverse side effects being higher in the BVS857-treated group.

The most common treatment-related side effects were inflammation of the nose and pharynx, and headache. In general the treatment was found to be safe without inducing any serious problems.

Repeated treatment with BVS857 induced a significant increase in IGF-1 levels up to a mean value of 788 ng/mL.

Evaluation by magnetic resonance imaging (MRI) scans revealed that BVS857 could induce a significant, but mild, improvement of thigh muscle volume (TMV) — a marker of muscle wasting — compared to initial values. Also, TMV in BVS857-treated patients remained stable during the trial, while it decreased in the placebo group.

However, new assessment of TMV approximately 21 and 48 days after completion of the treatment showed no significant differences between the two groups.

BVS857 also failed to induce significant improvements on disease symptoms, as determined by the Adult Myopathy Assessment Tool score, and lean body mass when compared to placebo after 12 weeks.

“Overall, no significant differences were found in any of the motor functional measures between the BVS857 and placebo groups,” researchers wrote.

During the trial, about 72% of the patients on the BVS857 treatment group developed antibodies against both the investigational compound and natural IGF-1, which in 46% of the cases had a neutralizing effect. This enhanced immunoreactivity was fully resolved upon treatment discontinuation.

Collectively, these results demonstrated that IGF-1 pathway activation over a short period of time can significantly improve muscle volume in patients with Kennedy’s disease. Still, it failed to improve muscle strength and function.

“The evidence of preliminary efficacy over the short timeframe of 12 weeks in this study is encouraging and not previously described,” researchers wrote. “Activation of the IGF-1 pathway by other means, perhaps in combination with an anti-androgen drug, might be worth pursuing in future clinical trials.”

“We believe this result has implications for other clinical proof-of-concept studies in patients with muscle atrophy or wasting,” researchers concluded.

No comments:

Post a Comment

Please feel free to comment. By taking a moment to share your thoughts you add much to these articles. The articles then become more than just something I said or believe. In addition, by adding a comment, you might just be helping the next reader by sharing your opinion, experience, or a helpful tip. You can comment below or by sending me an email. I look forward to hearing from you.

Emerson said, "Life is a journey, not a destination."

Learning to live with Kennedy's Disease is my journey. It's not easy ... but its the only game in town.

This journey has no end-state or a final destination where I can say, "I finally made it!" It is, in fact, a long arduous journey of self-discovery.

"Life is a succession of lessons that must be lived to be understood." I have used the analogy that learning to live with Kennedy's Disease is like trying to cross a stream without getting wet. The only way is by using the stepping stones provided (my chosen life's path). Each step is a "life experience" and I must come to terms with that experience (regain my balance) before being able to take the next step. It is a slow and often challenging journey, but I am finding it very fulfilling.

"Nothing comes into experience uninvited." If I am to learn how to live with this disease I must be open (receptive) to both the good and the bad that accompanies these life experiences.

"Acceptance" is what I am working on today. For without it, I will never be able to take the next step.

__________________________________________

Don't Miss an Article:

If you want to receive an email of the latest published article, you can subscribe below under "Follow my blog by Email." Or, if you use a 'Reader' service, use the "Don't Miss an article - Subscribe today."

__________________________________________

Privacy and Disclaimer:

The LWKD Privacy Policy and Disclaimer can be found at the bottom of this page.

About the Author

To read Bruce's short stories or his other blog's posts, visit his author's website:

Total Pageviews

Privacy and Disclaimer

If you require any more information or have any questions about this privacy policy, please feel free to contact me by email me at CONTACT BRUCE above.

At https://kennedysdisease.blogspot.com/, hereafter known as LWKD, I consider the privacy of visitors to be extremely important. This privacy policy document describes in detail the types of personal information is collected and recorded by LWKD and how I use it.

Log Filesike many other Web sites, LWKD makes use of log files. These files merely logs visitors to the site - usually a standard procedure for hosting companies and a part of hosting services's analytics. The information inside the log files includes internet protocol (IP) addresses, browser type, Internet Service Provider (ISP), date/time stamp, referring/exit pages, and possibly the number of clicks. This information is used to analyze trends, administer the site, track user's movement around the site, and gather demographic information. IP addresses, and other such information are not linked to any information that is personally identifiable.

Cookies and Web BeaconsLWKD uses cookies to store information about visitors' preferences, to record user-specific information on which pages the site visitor accesses or visits, and to personalize or customize the web page content based upon visitors' browser type or other information that the visitor sends via their browser.Children's InformationThis website is not intended for children under the age of thirteen (13). I believe it is important to provide added protection for children online. I encourage parents and guardians to spend time online with their children to observe, participate in and/or monitor and guide their online activity. LWKD does not knowingly collect any personally identifiable information from children under the age of 13. If a parent or guardian believes that LWKD has in its database the personally-identifiable information of a child under the age of 13, please contact me immediately (using the 'contact link' in the first paragraph) and I will use my best efforts to promptly remove such information from my records.

Online Privacy Policy OnlyThis privacy policy applies only to my online activities and is valid for visitors to my website and regarding information shared and/or collected there. This policy does not apply to any information collected offline or via channels other than this website.

Email InformationIf you choose to correspond with me through email, I may retain the content of your email messages together with your email address and our responses. I provide the same protections for these electronic communications that I employ in the maintenance of information received online, or by mail and telephone. As a convenience for my visitors, LWKD uses Feedburner a third-party service, for visitors who wish to receive the most current blog articles. You can unsubscribe from this blog delivery service at any time.

Disclosure Of Your Information LWKD does not sell, rent, lease or otherwise transfer any information collected whether automatically or through your voluntary action.

I may disclose information when legally compelled to do so, in other words, when I, in good faith, believe that the law requires it or for the protection of my legal rights or when compelled by a court or other governmental entity to do so.

ConsentBy using my website, you hereby consent to my privacy policy and agree to its terms.

DisclaimerThe views and opinions expressed on this blog are those strictly of the author. Information provided should not be considered medical advice nor the advice of a trained medical professional or physical therapist. The author has made a reasonable effort to ensure that all information provided is accurate, but as with any document, errors might occur. It is entirely the responsibility of the reader to determine the validity of any information provided. Any decisions made based upon the information provided are entirely the reader's responsibility. The author and the Kennedy's Disease Association do not accept any liability for any direct, indirect, special or consequential damages, or damages of any kind resulting from any cause through the use of any information obtained either directly or indirectly from this blog.

Learn more about Kennedy's Disease (SBMA)

Spinal Bulbar Muscular Atrophy (a.k.a. Kennedy's Disease) is an X-linked, adult onset, progressive muscle disorder.Because of its similarities to ALS, it is often initially misdiagnosed. Kennedy’s Disease does not show up until later in life (normally mid-20s to early 40s) and it gradually erodes your strength by killing off the muscles and motor neurons in your body.Doctors classify it as rare disorder and estimate that 1-in-40,000 men have it. Women with the defective gene are carriers.There is no treatment or cure for this disorder.If you want to learn more about Spinal Bulbar Muscular Atrophy, go to http://www.kennedysdisease.org. Or, Visit the KDA on Facebook

The Kennedy's Disease Association (KDA) is a 100% volunteer 501(c)3 tax-exempt California incorporated non-profit. 90¢ of every dollar donated goes to funding research for a treatment/cure and education. To help us find a cure, please consider making a donation for Kennedy's Disease research (http://www.kennedysdisease.org/find-cure).